Global trends in the distribution of cancer types among patients in oncology phase I trials, 1991–2015-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Global trends in the distribution of cancer types among patients in oncology phase I trials, 1991–2015

Published:2018-08-07 Issue:1 Volume:37 Page:166-174
ISSN:0167-6997
Container-title:Investigational New Drugs
language:en
Short-container-title:Invest New Drugs

Author:

Itahashi Kota,Shimizu Toshio,Koyama Takafumi,Kondo Shunsuke,Fujiwara Yutaka,Yamamoto Noboru

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s10637-018-0654-1.pdf

Reference22 articles.

1. Eisenhauer EA, O'Dwyer PJ, Christian M, Humphrey JS (2000) Phase I clinical trial design in cancer drug development. J Clin Oncol Off J Am Soc Clin Oncol 18(3):684–692

2. Wong KM, Capasso A, Eckhardt SG (2016) The changing landscape of phase I trials in oncology. Nat Rev Clin Oncol 13(2):106–117. https://doi.org/10.1038/nrclinonc.2015.194

3. Lopez J, Harris S, Roda D, Yap TA (2015) Precision medicine for molecularly targeted agents and immunotherapies in early-phase clinical trials. Transl Oncogenomics 7(Suppl 1):1–11. https://doi.org/10.4137/tog.s30533

4. Roper N, Stensland KD, Hendricks R, Galsky MD (2015) The landscape of precision cancer medicine clinical trials in the United States. Cancer Treat Rev 41(5):385–390. https://doi.org/10.1016/j.ctrv.2015.02.009

5. Herbst RS, Baas P, Kim DW, Felip E, Perez-Gracia JL, Han JY, Molina J, Kim JH, Arvis CD, Ahn MJ, Majem M, Fidler MJ, de Castro G Jr, Garrido M, Lubiniecki GM, Shentu Y, Im E, Dolled-Filhart M, Garon EB (2016) Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet (London, England) 387(10027):1540–1550. https://doi.org/10.1016/s0140-6736(15)01281-7

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Selumetinib: a selective MEK1 inhibitor for solid tumor treatment;Clinical and Experimental Medicine;2022-02-16

2. Infection risk with PI3K-AKT-mTOR pathway inhibitors and immune checkpoint inhibitors in patients with advanced solid tumours in phase I clinical trials;ESMO Open;2020

3. Realizing better doctor-patient dialogue about choices in palliative care and early phase clinical trial participation: towards an online value clarification tool (OnVaCT);BMC Palliative Care;2019-11-29

4. Improved survival among patients enrolled in oncology phase 1 trials in recent decades;Cancer Chemotherapy and Pharmacology;2019-11-19

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3